91̽»¨

University 91̽»¨
Image
Mass spectrometer lab at the Proteomics Core Facility

Proteomics (PCF)

The Proteomics Core Facility offers scientific expertise and advanced instrumentation for proteome studies within medicine and life science. Our platform is available to researchers at the University 91̽»¨ as well as to external users from other universities or industry. PCF is involved in approximately 300 projects per year. Most projects we are involved in are global proteomic analyses, in which thousands of proteins can be identified and quantified in an unbiased manner.

NEWS at PCF

Plasma proteomics

The Proteomics Core Facility (PCF) has implemented Biognosys' P2 Enrichment technology, enabling quantification of up to 7,000 plasma proteins—a major leap from previous capabilities. Integrated with automated sample preparation workflows, and TimsTOF HT and Orbitrap Astral MS instruments, the platform delivers high-throughput, reproducible and clinically relevant data for biomarker discovery, disease understanding, and precision medicine.

Read more under "Our Research Support and Equipment" and under GU News

Our Research Networks

BioMS

Since 2016 we are one of the nodes of the Swedish National Infrastructure for Biological Mass Spectrometry, BioMS, supported by the Swedish Research Council. For projects within Clinical Proteomics and Large Scale Quantitative Proteomics contact our project coordinator Annika Thorsell. Moreover, Ekaterina Mirgorodskaya is coordinating projects within Glycoproteomics and Glycomics. Please read more on the BioMS webpage.

 

Swedish Research Council

The Swedish Research Council is Sweden’s largest governmental research funding body and supports research of the highest quality in all scientific fields. 

SciLifeLab

In 2021, we joined the 91̽»¨ for Life Laboratory, a national research infrastructure funded by the Swedish government. Within the Proteomics units, we are supporting glycoproteomics and MS proteomics projects. Please find more information on the SciLifeLab homepage.